Officials have yet to keep their promise to disclose how many people are signing up during a special Obamacare enrollment season.» Read More
Not all protein powders or vitamins are created equal, according to San Francisco start-up LabDoor.
Three major insurers and a nonprofit group are planning to launch an online tool that will tell consumers the prices of medical procedures.
Medicaid enrollment has risen in most anti-Obamacare states, which may further strain some of their budgets.
Ian Read, chief executive of Pfizer, hit back at claims some of AstraZeneca’s drugs may be delayed if Pfizer is successful in its bid for the company.
Chinese police on Wednesday said they had charged the British former China head of drugmaker GlaxoSmithKline and other colleagues with corruption, after a 10- month probe found they paid billions of yuan in bribes to doctors and hospitals.
U.K. hearings over a potential AstraZeneca-Pfizer tie-up was a chance to discuss "Entente Cordiale" and whether leopards will change their spots.
The CEO of AstraZeneca told CNBC the U.K. pharmaceutical giant was big enough to thrive alone, but would still consider a takeover bid.
Consumers have gained more than $3 billion in benefits from an Obamacare rule forcing insurers to keep a tight rein on overhead costs.
Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.
Valeant said it planned to "improve" its $47 billion takeover offer for drugmaker Allergan, a day after the U.S. company rejected the bid.
U.S. drugmaker Pfizer's boss was grilled by UK lawmakers on his commitment to British research spending and jobs.
Virginia and Washington state's Obamacare prices for 2015 don't look so scary on average, but a few other states could be in for some sticker shock.
The Corporate Angel Network, which gets cancer patients free flights on corporate jets, recently flew its 45,000th passenger.
U.S. medical firm Allergan rejected the unsolicited takeover offer from Valeant Pharmaceuticals, saying it substantially undervalued the company.
Pfizer has launched a fight back against critics of its proposed takeover of AstraZeneca, but did not make any fresh promises on jobs or investment.
Pfizer's $106 billion takeover approach for AstraZeneca is facing mounting scrutiny as senior U.S. politicians weigh in.
Abandoning Obamacare's looming rule that most employers must offer workers health coverage would have little effect on the overall uninsured rate.
The debate in individual states about whether to expand Medicaid eligibility is getting renewed attention as advocates argue it makes financial sense
Allergan is set to reject a $46bn offer by rival Valeant Pharmaceutical, a move likely to spur a takeover battle in the US drug-making industry. FT.
Health insurers are reluctant to cover marijuana, in part because of conflicting laws.
Get the best of CNBC in your inbox